Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
Top Cited Papers
Open Access
- 1 January 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cardiovascular Diabetology
- Vol. 11 (1), 3
- https://doi.org/10.1186/1475-2840-11-3
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretinsCardiovascular Diabetology, 2011
- Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled studyDiabetes, Obesity and Metabolism, 2010
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetesBMC Endocrine Disorders, 2010
- Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapiesJournal of the American Society of Hypertension, 2009
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesThe New England Journal of Medicine, 2009
- Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes TrialsDiabetes Care, 2009
- Cardiovascular Outcomes in Trials of Oral Diabetes Medications - A Systematic ReviewArchives of Internal Medicine, 2008
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008